Skip to main content
Press Release

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

By June 1, 2020May 26th, 2021No Comments

Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company developing targeted anti-MARCKS technology for the treatment of ARDS [Acute Respiratory Distress Syndrome], cancer and other difficult to treat diseases, today announced new data from a Phase 2 study of its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), will be presented during the American Thoracic Society 2020 (ATS) virtual meeting in August 2020. Kenneth Adler, Ph.D., Professor in the Department of Molecular Biomedical Sciences at North Carolina State University and Chief Scientist of Biomarck Pharmaceuticals will discuss the information during a poster discussion.

“We are pleased to present these compelling results at this year’s ATS conference, which show that inhaled BIO-11006 decreases metastasis and tumor progression, and increases the overall response rate and survival in patients with advanced NSCLC. BIO-11006 appears to have a unique mechanism of action in blocking inflammation and cytokine production in the lungs of patients,” said Professor Adler. “Inflammation and the cytokine storm are well known as a major contributor to ARDS. It is entirely possible that, by blocking inflammation and the cytokine storm in the tumor microenvironment of metastatic lung cancer and of the injured lung in ARDS, BIO-11006 is acting, at least in part, through this similar mechanism of action.”

The full poster entitled, “An Inhaled MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) – Inhibitory Drug, BIO-11006, Elicited a Statistically-Significant Result (p= 0.02) in Overall Response Rate (ORR) After 3 Months Compared to Standard of Care Chemotherapy in a Phase 2 Trial of Late Stage Non-Small Cell Lung Cancer (NSCLC),” discussion session is included in the ATS Journal – here.

About BIO-11006

BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. The investigational compound was identified and advanced from animal models and human tissue testing into Phase 2 clinical studies based on the research of Dr. Kenneth Adler, Professor in the Department of Molecular Biomedical Sciences at North Carolina State University.

BIO-11006 is being investigated for the treatment of ARDS, Chronic Obstructive Pulmonary Disease (COPD) and Non-Small Cell Lung Cancer (NSCLC). It has a complete pre-clinical package of toxicology and pharmacology data and has been through Phase 1 and 2a trials involving over 300 subjects. BIO-11006 has a well-established safety profile across multiple placebo-controlled studies.

Biomarck Pharmaceuticals, Ltd., is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, confirming safety and efficacy in these three potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis.

Graham G. Lumsden
President and CEO
info@biomarck.com

Fill out my online form.

This press release may contain forward-looking statements. Forward-looking statements are not guarantees, and they involve risks, uncertainties, and assumptions. The information in the press release should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.